SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held from December 1-4, 2018 in San Diego. The following abstracts were published today are now available on the ASH website at www.hematology.org.
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study (Abstract # 2937)
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma - Clinical Studies: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Location: San Diego Convention Center, Hall GH
Identification of Tipifarnib Sensitivity Biomarkers in T-cell Tumor Cell Lines (Abstract # 2851)
Session Name: 621. Lymphoma-Genetic / Epigenetic Biology: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Location: San Diego Convention Center, Hall GH
Following presentation at the meeting, the posters will be available on Kura's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the company is conducting a registration-directed trial in recurrent or metastatic patients with HRAS mutant head and neck squamous cell carcinomas. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. The company’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Contacts
Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com
Source: Kura Oncology, Inc.
